scholarly journals Acute pancreatitis following Pfizer-BioNTech COVID-19 vaccine

2021 ◽  
Vol 0 ◽  
pp. 1-3
Author(s):  
Ammar A. Albokhari ◽  
Abdulrahman T. Alsawas ◽  
Abdulmajeed Khan ◽  
Ghufran A. Bukhari

The coronavirus disease of 2019 (COVID-19) discovered in China in early December 2019. The Saudi Food and Drug Authority approved the registration of the Pfizer-BioNTech COVID-19 vaccine in Saudi Arabia on December 10, 2020, and on May 10, 2021, Pfizer-BioNTech was given emergency authorization for use of the vaccine in children aged 12 to 15 years. Saudi Arabia’s Ministry of Health started the vaccination phase for ages 12 to 18 years for the Pfizer-BioNTech COVID-19 vaccine on June 27, 2021. An insulin-dependent diabetic 15-year-old female patient admitted to the medical ward diagnosed with acute pancreatitis nine days after being administered her first dose of the Pfizer-BioNTech COVID-19 vaccine. She presented with an amylase level of 340 U/L, lipase level of 937 U/L. She was discharged after eight days of hospitalization with no complications. Medical investigations were unable to link the diagnosis to any known etiology. Medical journals have reported numerous cases of acute pancreatitis in the adult population after Pfizer-BioNTech COVID-19 vaccination. We believe that our case is the first to present with acute pancreatitis after the first dose of the Pfizer-BioNTech COVID-19 vaccine in a teenager population.

Author(s):  
Ammar Albokhari ◽  
Abdulrhman Alsawas ◽  
Mohammad Adnan ◽  
Abdulaziz Alasmari ◽  
Sarah Aljuhani ◽  
...  

Coronavirus disease 2019 (COVID-19) originated in China in early March 2019. Saudi Food and Drug Authorityapproved the registration of the Pfizer-BioNTech COVID-19 vaccine in Saudi Arabia on December 10, 2020 and on May 10, 2021, Pfizer-BioNTech was given an authorized emergency use in 12 to 15 years old children. Saudi Arabia’s Ministry of Health started Pfizer-BioNTech COVID-19 vaccination for 12 to 18 years old on June 27, 2021. Here we have a case of 16-year-old female admitted to the medical ward diagnosed with acute inflammatory transverse myelitis after two weeks from second dose of the Pfizer-BioNTech COVID-19 vaccine. The diagnosis was based on normal laboratory workup but significant radiological findings. She was discharged after a full recovery.There are multiple cases of post-vaccine acute inflammatory transverse myelitisshared by medical journals, but due to lack of literature review for the teenager population, we think our case may be the first case of acute inflammatory transverse myelitis following second dose of Pfizer-BioNTech COVID-19 vaccine in this population.


2021 ◽  
Vol 0 ◽  
pp. 1-4
Author(s):  
Ammar A. Albokhari ◽  
Abdulrahman Alsawas ◽  
Mohammad H. Adnan ◽  
Abdulaziz Alasmari ◽  
Sarah Aljuhani ◽  
...  

Coronavirus disease 2019 (COVID-19) originated in China in early March 2019. Saudi Food and Drug Authority approved the registration of the Pfizer-BioNTech COVID-19 vaccine in Saudi Arabia on December 10, 2020, and on May 10, 2021, Pfizer-BioNTech was given an authorized emergency use in 12–15-years-old children. Saudi Arabia’s Ministry of Health started Pfizer-BioNTech COVID-19 vaccination for 12–18-years-old on June 27, 2021. Here, we have a case of a 16-year-old female admitted to the medical ward diagnosed with acute inflammatory transverse myelitis after 2 weeks from second dose of the Pfizer-BioNTech COVID-19 vaccine. The diagnosis was based on normal laboratory workup but significant radiological findings. She was discharged after a full recovery. There are multiple cases of post-vaccine acute inflammatory transverse myelitis shared by medical journals, but due to lack of literature review for the teenager population, we think our case may be the first case of acute inflammatory transverse myelitis following second dose of Pfizer-BioNTech COVID-19 vaccine in this population.


2018 ◽  
Vol 4 (3) ◽  
pp. 497-503
Author(s):  
Yousef Ahmed Alomi ◽  
Saeed Jamaan Alghamdi ◽  
Radi Abdullah Alattyh

Objective: To explore the National Survey of Drug Information Centers practice in Saudi Arabia: Leadership and Practice management at Ministry of Health hospital. Method: It is a cross-sectional four months national survey of Drug Information Services at Ministry of Health hospital. It contained ten domains with 181 questions designed by the authors. It was derived from Internal Pharmaceutical Federation, American Society of Health-System Pharmacists best practice guidelines. This survey was distributed to forty hospital pharmacies that run drug information services. In this study, domain of Drug Monitoring and Patient Counselling System explored and analyzed. It consisted of eight questions about the written policy and procedure and application methods for Leadership and Practice management in the drug information centers. All analysis was done through survey monkey system. Results: The survey distributed to 45 of hospitals, the response rate, was 40 (88.88%) hospitals. The highest score of the DIC had policy and procedures with a clear mission, vision, and values were Evidence of valid Saudi Council of Health Specialties license to practice in Saudi Arabia did not exist in 3 (7.5%) hospitals while 30 (75%) of hospitals 100% applied the elements. The highest score of the Drug information centers had a space, adequate furniture, hours of operation were determined and announced as well as there was a qualified and licensed staffing. All Drug Information Centers staff had valid licenses from Saudi Commission for Health Specialties to practice in Saudi Arabia, did not exist in 6 (15%) hospitals while 30 (75%) of hospitals 100% applied the elements. The highest score of the Drug Information Centers Supervisor, reports workload statistics to the appropriate and leadership number of Full Time Employee staff and actual workload published was the answering question depends on the priority of the question did not exist in 6 (15%) hospitals while only 22 (55%) of hospitals 100% applied the elements. The highest score of the Drug Information Centers showed evidence of Quality Improvement, and the process for Drug Information Centers Networking. The reporting any questionable drug quality to Pharmacy director, did not exist in 4 (10 %) hospitals while only 25 (62.5%) of hospitals 100% applied the elements. Conclusion: There were an acceptable implementation leadership and practice management in drug information centers practice. The drug information centers workload analysis and quality management should improve. Drug information centers network indication required an implementation to improve the services at Ministry of Health hospital in Kingdom of Saudi Arabia.


Diabetes ◽  
1976 ◽  
Vol 25 (10) ◽  
pp. 955-960 ◽  
Author(s):  
J. E. Gerich ◽  
M. Lorenzi ◽  
E. Tsalikian ◽  
N. V. Bohannon ◽  
V. Schneider ◽  
...  

Diabetes ◽  
1982 ◽  
Vol 31 (1) ◽  
pp. 46-52 ◽  
Author(s):  
M. C. Foss ◽  
F. V. Vlachokosta ◽  
L. N. Cunningham ◽  
T. T. Aoki

Diabetes ◽  
1985 ◽  
Vol 34 (11) ◽  
pp. 1127-1133 ◽  
Author(s):  
R. K. Mayfield ◽  
P. V. Halushka ◽  
H. J. Wohltmann ◽  
M. Lopes-Virella ◽  
J. K. Chambers ◽  
...  

Diabetes ◽  
1985 ◽  
Vol 34 (3) ◽  
pp. 241-245 ◽  
Author(s):  
G. Ward ◽  
L. C. Harrison ◽  
J. Proietto ◽  
P. Aitken ◽  
A. Nankervis

Sign in / Sign up

Export Citation Format

Share Document